<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pain Manag</journal-id><journal-id journal-id-type="iso-abbrev">Pain Manag</journal-id><journal-id journal-id-type="pmc-domain-id">3075</journal-id><journal-id journal-id-type="pmc-domain">pmt</journal-id><journal-title-group><journal-title>Pain Management</journal-title></journal-title-group><issn pub-type="ppub">1758-1869</issn><issn pub-type="epub">1758-1877</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12001541</article-id><article-id pub-id-type="pmcid-ver">PMC12001541.1</article-id><article-id pub-id-type="pmcaid">12001541</article-id><article-id pub-id-type="pmcaiid">12001541</article-id><article-id pub-id-type="pmid">40162830</article-id><article-id pub-id-type="doi">10.1080/17581869.2025.2479411</article-id><article-id pub-id-type="publisher-id">2479411</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Methadone in the madness: a case series and review of methadone management in hospital settings</article-title><alt-title alt-title-type="left-running-head">C. F. MULLINS ET AL.</alt-title><alt-title alt-title-type="right-running-head">PAIN MANAGEMENT</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2459-6251</contrib-id><name name-style="western"><surname>Mullins</surname><given-names initials="CF">Cormac F.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walsh</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names initials="J">Joseph</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><aff id="aff0001"><label>a</label>Department of Pain Medicine, <institution-wrap><institution>South Infirmary Victoria University Hospital</institution></institution-wrap>, <city>Cork</city>, <country>Ireland</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>Department of Anaesthesiology and Pain Medicine, Cork University Hospital</institution></institution-wrap>, <city>Cork</city>, <country>Ireland</country></aff><aff id="aff0003"><label>c</label>Department of Anaesthesiology and Pain Medicine, <institution-wrap><institution>St. James&#8217;s Hospital</institution></institution-wrap>, <city>Dublin</city>, <country>Ireland</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Cormac F. Mullins <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:cormacmullins1@gmail.com">cormacmullins1@gmail.com</email> Department of Pain Medicine, South Infirmary Victoria University Hospital, <addr-line>Old Blackrock Road, Ballintemple</addr-line>, <city>Cork</city><postal-code>T12 X23H</postal-code>, <country>Ireland</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>3</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>15</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">486731</issue-id><fpage seq="4">191</fpage><lpage>198</lpage><pub-history><event event-type="pmc-release"><date><day>31</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-17 10:26:06.673"><day>17</day><month>04</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>11</day><month>4</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>11</day><month>4</month><year>2025</year></date></event><event event-type="received"><date><day>19</day><month>6</month><year>2024</year></date></event><event event-type="accepted"><date><day>11</day><month>3</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IPMT_15_2479411.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="IPMT_15_2479411.pdf"/><abstract><title>ABSTRACT</title><p>The management of patients on chronic methadone therapy for opioid use disorder presents unique pharmacological and psychosocial challenges in hospital settings. This case series discusses complexities such as methadone&#8217;s variable pharmacokinetics, alternatives to oral methadone and conversion ratios. Additionally, it outlines the nuances around the psychosocial considerations of methadone therapy and addressing addiction-related behaviors without compromising patient dignity. The review calls for individualized care plans with uninterrupted opioid agonist therapy to meet the baseline opioid requirements and pro-active pain management plans. Enhanced clinician education and better real-world data to guide methadone management is important to improve outcomes for this vulnerable patient cohort.</p></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>Methadone use is becoming more common for the treatment of opioid use disorder (OUD) and chronic pain. Methadone use can present specific challenges, both in how it works in the body and how it affects patients emotionally and socially. This article discusses three patient cases that highlight these challenges.</p><p>In the first case, a woman with a history of OUD had surgery but experienced severe pain and withdrawal symptoms when her usual methadone treatment was interrupted. As she could no longer eat after the surgery, the methadone had to be converted into an equivalent dose of a related drug, which caused problems.</p><p>The second case involved a man who was admitted to hospital for surgery and was prescribed methadone in the community, but only took half of his dose while selling the rest. He was administered the full dose according to hospital policy, leading to an overdose. His pain control was challenging postoperatively.</p><p>The third case centered on a woman who was taking methadone in the community which was not prescribed, complicating her treatment in the hospital after surgery.</p><p>Overall, the article emphasizes that managing acute pain in patients on chronic methadone therapy requires special attention. It is essential to continue opioid treatment and use a variety of pain management strategies to ensure patients receive respectful and effective care. Misunderstandings about OUD can lead to stigma and inadequate treatment, highlighting the need for more research on how to best manage methadone in hospital settings.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Opioid agonist therapy</kwd><kwd>opioid dependence</kwd><kwd>perioperative management</kwd><kwd>acute pain</kwd><kwd>chronic pain</kwd><kwd>pain management</kwd></kwd-group><support-group><funding-group><funding-statement>This paper was not funded.</funding-statement></funding-group></support-group><counts><fig-count count="1"/><table-count count="1"/><ref-count count="55"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><label>1.</label><title>Introduction</title><p>Chronic methadone treatment is increasingly common in daily clinical practice either for opioid use disorder (OUD) and/or for chronic pain management [<xref rid="cit0001" ref-type="bibr">1</xref>]. Methadone can pose unique clinical challenges from a pharmacological and a psychosocial perspective, especially in the acute hospital environment. Methadone possesses complex pharmacokinetics and pharmacodynamics and exhibits significant inter-individual variation in metabolism and conversion to other opioids [<xref rid="cit0002" ref-type="bibr">2</xref>]. The development of tolerance, opioid-induced hyperalgesia and potentially fatal respiratory depression in overdose adds further nuance [<xref rid="cit0003" ref-type="bibr">3</xref>]. The stigma caused by OUD can lead to many misconceptions in this patient population which can impact access to non-judgmental and patient-centered care [<xref rid="cit0004" ref-type="bibr">4</xref>]. This case series aims to invite reflection on some of the important considerations in managing those on chronic methadone treatment in the acute hospital through three short case vignettes. A literature search was conducted on PubMed (1996-present) utilizing the following MeSH terms: &#8220;methadone,&#8221; &#8220;opioid-related disorders&#8221; and &#8220;acute pain.&#8221; The last search was performed on 28 January 2025. Informed patient consent was obtained prior to the inclusion of all cases presented in this series in anonymized form.</p><sec disp-level="2" id="s0001-s2001"><label>1.1.</label><title>CASE 1: continuing baseline methadone in the peri-operative setting</title><p>A 52-year-old female presented to the emergency department with a strangulated hernia requiring surgical resection. She had a prior history of opioid use disorder (OUD) and was on opioid maintenance therapy of 125&#8201;mg methadone for the past 9&#8201;years. Her past medical history was significant for borderline personality disorder, HIV and hepatitis C.</p><p>She underwent a laparotomy and a resection of the strangulated segment of bowel with a primary anastomosis. A nasogastric (NG) tube was inserted intraoperatively which was kept in postoperatively and placed on free drainage. As she was placed nil per oral, the anesthetist discontinued her methadone and she was started on an oxycodone patient-controlled analgesia (PCA) pump with a 1&#8201;mg bolus every 5&#8201;minutes in lieu of the oral methadone. She was reviewed on postoperative day 1 by the acute pain service in a six-bed bay in a general surgical ward where she was acutely agitated, reporting severe pain and was insistent that she was in withdrawal from her methadone. A decision was made to recommence her oral methadone and her NG tube was clamped for one hour to facilitate administration of this. After the NG tube was unclamped, a significant amount of green fluid drained spontaneously from the NG tube making it difficult to ascertain how much of the methadone was absorbed. The oral methadone was instead stopped and the PCA oxycodone was uptitrated instead. A background infusion of 1&#8201;mg/hr was commenced which was increased gradually to 3&#8201;mg/hr with a bolus of 2&#8201;mg every 5&#8201;minutes. Satisfactory pain control was achieved with this regimen. After three days, the NG tube was removed and the patient was re-instituted on the same dose of oral methadone. She was discharged from hospital after one week on the same dose of methadone and no additional opioids.</p></sec><sec disp-level="2" id="s0001-s2002"><label>1.2.</label><title>CASE 2: verifying methadone dose prescribed in the community</title><p>A 39-year-old male was admitted for a laryngectomy on a background of supraglottic laryngeal cancer and a prior history of OUD. He was being prescribed methadone 80&#8201;mg at a community-based drug treatment center. Preoperatively on hospital admission, he was prescribed the same dose of methadone which was administered under direct nursing supervision in accordance with hospital policy. A few hours after ingestion of his usual prescribed methadone dose, the patient was found unresponsive on the ward with a low respiratory rate and pinpoint pupils. The intensive care team was called and his breathing was supported with bag-mask ventilation and was administered naloxone 200mcg. His respiratory rate improved spontaneously. When the patient had recovered, he was questioned about the correct dose of his methadone. He admitted that while he was prescribed 80&#8201;mg methadone at the drug treatment center, he only takes 40&#8201;mg and sells the other 40&#8201;mg in the community. He subsequently underwent his laryngectomy. His pain was poorly controlled post-operatively. His methadone was recommenced at 20&#8201;mg daily and an oxycodone PCA 1&#8201;mg bolus every five minutes was started. He was referred to the addiction psychiatry team to manage his methadone prescription and to monitor his condition in the community.</p></sec><sec disp-level="2" id="s0001-s2003"><label>1.3.</label><title>CASE 3: consumption of nonprescribed methadone in the community</title><p>A 46-year-old female with a background of Crohn&#8217;s disease and a previous subtotal colectomy 10&#8201;years ago was admitted with a small bowel obstruction. The patient reported longstanding chronic abdominal pain following her abdominal surgery 10&#8201;years previously and had been taking escalating doses of tramadol 100&#8201;mg approximately every 1&#8211;2&#8201;hours of her own accord. Furthermore, to control her pain, she reported using 60-70&#8201;mg of non-prescribed methadone per day.</p><p>She underwent a laparoscopy and adhesiolysis. As there was no source to verify her methadone dose, she was started on a PCA morphine 1&#8201;mg/hour infusion with 1&#8201;mg every 5&#8201;minutes bolus postoperatively, which was increased to a 2&#8201;mg bolus on the first postoperative day. An inpatient referral was made to the addiction psychiatry team to facilitate a review of her methadone use in the community and to the chronic pain team to manage her chronic abdominal pain. She was started on methadone 20&#8201;mg prior to discharge and given a follow-up appointment with the community drug treatment center.</p></sec></sec><sec disp-level="1" id="s0002"><label>2.</label><title>Discussion</title><sec disp-level="2" id="s0002-s2001"><label>2.1.</label><title>Treatment of opioid use disorder (OUD)</title><p>OUD is a chronic relapsing disorder associated with a myriad of biopsychosocial problems [<xref rid="cit0005" ref-type="bibr">5</xref>]. Medications routinely used in the management of this condition to good effect include methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine occupy the opioid receptor thereby offsetting opioid withdrawal symptoms and attenuating opioid activity at this site, while naltrexone blocks the effect of other opioid agonists [<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0007" ref-type="bibr">7</xref>]. Methadone and buprenorphine have been associated with a reduction in all-cause and opioid-related mortality for this indication [<xref rid="cit0008" ref-type="bibr">8</xref>]. Oral methadone possesses the largest evidence base for effectiveness, with longer duration of treatment associated with improved outcomes including reduced risk of fatal overdose, reduction in crime and subjective improvement in quality of life [<xref rid="cit0009" ref-type="bibr">9</xref>]. While a single daily dose of 30&#8201;mg methadone can prevent the onset of withdrawal symptoms in the majority of individuals with OUD, a higher dose (60-100&#8201;mg/day) is more effective in achieving abstinence from other opioid use through inducing opioid tolerance and reduction of the reward effect of opioids [<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>]. Effectiveness can be limited by lack of adherence to treatment, diversion and misuse of methadone, high rate of relapse and increased risk of overdose after discontinuing treatment [<xref rid="cit0005" ref-type="bibr">5</xref>]. Furthermore, many patients can have difficulty accessing methadone treatment for OUD due to the highly regulated system that oversees its use.</p></sec><sec disp-level="2" id="s0002-s2002"><label>2.2.</label><title>Unique pharmacokinetics and Pharmacodynamics</title><p>Methadone is a long-acting synthetic opioid which acts as a full mu-opioid agonist and also possesses additional analgesic activity through antagonism of the NDMA receptor and catecholamine reuptake [<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref>]. It is absorbed through the stomach and possesses a bioavailability of 85% with a peak plasma concentration after oral administration of approximately 2&#8211;6&#8201;hours. Its oral to parenteral potency ratio is 1:2 from single dose studies [<xref rid="cit0006" ref-type="bibr">6</xref>]. It can be absorbed sublingually and it has been used for breakthrough cancer pain through this route [<xref rid="cit0014" ref-type="bibr">14</xref>]. Methadone is highly lipophilic and once absorbed, it rapidly moves into lipophilic tissues from the blood compartment [<xref rid="cit0015" ref-type="bibr">15</xref>]. Once lipophilic tissues are saturated then an equilibrium is reached between the lipid and blood compartments and slow elimination begins with a variable elimination half-life of between 5&#8211;130&#8201;hours (average 22&#8201;hours) [<xref rid="cit0015" ref-type="bibr">15</xref>]. For these reasons, it typically takes between four to five days to reach a steady state plasma concentration [<xref rid="cit0016" ref-type="bibr">16</xref>]. Methadone is predominantly metabolized by CYP450, particularly 3A4 and drugs that inhibit or induce these enzymes may affect its duration of action [<xref rid="cit0017" ref-type="bibr">17</xref>].</p></sec><sec disp-level="2" id="s0002-s2003"><label>2.3.</label><title>Acute pain in opioid use disorder</title><p>Managing acute pain, either post-surgery or trauma, in patients on methadone treatment for OUD can be challenging due to baseline opioid requirements and associated opioid tolerance and increased pain sensitivity or opioid-induced hyperalgesia [<xref rid="cit0018" ref-type="bibr">18</xref>]. Misperceptions may exist that the usual maintenance methadone dose may be sufficient for postoperative analgesia [<xref rid="cit0018" ref-type="bibr">18</xref>]. This is illustrated in the first case where the total deliverable dose of the morphine PCA, which was prescribed in lieu of chronic methadone therapy, was insufficient even to cover baseline opioid requirements, without consideration of postoperative analgesia requirements. While methadone has a long elimination half-life and this can prevent opioid withdrawal symptoms for 24&#8211;48&#8201;hours, its effect on pain suppression is much shorter (4&#8211;8&#8201;hours) [<xref rid="cit0019" ref-type="bibr">19</xref>].</p><p>The usual principles of treating acute pain apply in those on chronic methadone treatment including optimizing non-opioids first and employing multi-modal methods of analgesia including regional analgesic techniques. Nonopioids can include pharmacological (topical or oral NSAIDs, paracetamol and antineuropathic agents if indicated) and nonpharmacological options (e.g., ice, heat, stretching, immobilization and rest) [<xref rid="cit0020" ref-type="bibr">20</xref>]. Patients on chronic methadone treatment, however, will typically require an increase in their total opioid dose, due to increased pain sensitivity and opioid-induced hyperalgesia [<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref>]. As they will have developed tolerance to methadone, opioid cross-tolerance will typically entail that higher and more frequent doses of additional opioid analgesics are required to achieve adequate analgesia [<xref rid="cit0023" ref-type="bibr">23</xref>].</p></sec><sec disp-level="2" id="s0002-s2004"><label>2.4.</label><title>Prescribing reluctances</title><p>A reluctance can exist among clinicians to prescribe additional opioids to those with OUD for fear that this might precipitate a relapse or an overdose, which unfortunately, can lead to severe under-treatment of acute pain in this vulnerable cohort of patients [<xref rid="cit0018" ref-type="bibr">18</xref>]. The stress response associated with inadequate treatment of pain is likely to be an even greater risk factor for relapse in comparison to appropriately prescribed additional opioid analgesia [<xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0025" ref-type="bibr">25</xref>]. There may be concern that starting additional opioid analgesics in addition to their current medications for OUD may precipitate a CNS or respiratory depression; however, acute pain has been demonstrated to work as a natural antagonist to opioid-induced respiratory and CNS depression, as evidenced by studies that show that regional anesthesia can increase the risk of respiratory depression in the setting of opioids by reducing the nociceptive input to the brain [<xref rid="cit0026" ref-type="bibr">26</xref>,<xref rid="cit0027" ref-type="bibr">27</xref>]. Hence, these concerns should not be barriers to proactive, aggressive administration of analgesia in the setting of acute severe pain in this population [<xref rid="cit0018" ref-type="bibr">18</xref>]. Those with OUD are up to three times more likely to discharge against medical advice, with untreated withdrawal, uncontrolled pain, stigma, and hospital restrictions as possible causative factors [<xref rid="cit0028" ref-type="bibr">28</xref>].</p></sec><sec disp-level="2" id="s0002-s2005"><label>2.5.</label><title>Peri-operative analgesia challenges in chronic methadone treatment</title><p>For those on chronic methadone treatment requiring surgery, baseline oral methadone should always be continued where possible [<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0030" ref-type="bibr">30</xref>] (<xref rid="f0001" ref-type="fig">Figure 1</xref>). Two of the cases presented here illustrate the difficulties involved in managing acute pain in the perioperative period for those on chronic methadone treatment. If the oral route is not available, methadone can be given intramuscularly (IM) or subcutaneously (SC); however, as these are not common routes for delivery of methadone, physicians or ward staff may not be comfortable prescribing or administering this. One half to two-thirds of the total daily oral dose of methadone can be administered IM or SC in 2&#8211;4 divided doses) [<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>]. For example, in case one, the patient was taking 125&#8201;mg methadone orally once a day; the equivalent intramuscular dose of methadone would be approximately 15&#8201;mg-20&#8201;mg 6&#160;hourly or 30-40&#8201;mg 12&#160;hourly (total 60-80&#8201;mg daily). However, wide individual variability exists with methadone conversion and the intramuscular route can be associated with variable absorption [<xref rid="cit0032" ref-type="bibr">32</xref>].
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Management algorithm for methadone in acute pain presentation including in the perioperative period.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IPMT_A_2479411_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IPMT_A_2479411_F0001_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="s0002-s2006"><label>2.6.</label><title>Intravenous methadone and pharmacokinetics</title><p>Methadone has been administered intravenously but typically this is reserved for the intraoperative setting, such as a single dose at induction for procedures expected to cause severe postoperative pain, or in a palliative care setting for advanced cancer when other opioid analgesics have been unsuccessful [<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>]. Intravenous methadone can be employed under specialist supervision for postoperative pain, but this should be confined to a critical care bed with monitoring of respiratory rate and level of sedation and support of an acute pain service familiar with the use of methadone. When converting to intravenous methadone from the oral route, the daily dose of oral methadone can be reduced by 50% and infused over 24&#8201;hours or, alternatively, divided and administered at 6&#8211;8&#160;hourly intervals [<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>]. IV methadone appears to increase the risk of QT-interval prolongation and serious arrhythmia (torsades de pointes); therefore, a screening ECG should be conducted prior to initiation of therapy, at 24&#8201;hours and after 4&#8201;days of therapy [<xref rid="cit0036" ref-type="bibr">36</xref>]. Postoperatively, methadone has been administered as patient-controlled analgesia (PCA), however, the pharmacokinetic profile of methadone makes it challenging to use as a PCA for acute pain [<xref rid="cit0037" ref-type="bibr">37</xref>]. Its high lipophilicity ensures a rapid onset of action, however the long and variable elimination half-life can result in accumulation during the titration phase and toxic effects and overdose can occur several hours or days after administration [<xref rid="cit0037" ref-type="bibr">37</xref>].</p></sec><sec disp-level="2" id="s0002-s2007"><label>2.7.</label><title>Conversion to other opioids</title><p>If parenteral methadone is not possible, then an alternative opioid will need to be prescribed for opioid replacement therapy &#8211; termed &#8216;opioid rotation.&#8217; Opioid rotation is typically performed for two reasons. Either a patient requires an alternative route for their opioid, either out of necessity or convenience; or the patient is unable to achieve the desired analgesia without encountering disabling side effects and an alternative opioid may create a better balance between analgesia and adverse effects [<xref rid="cit0038" ref-type="bibr">38</xref>]. Normally, calculating the correct dose for any opioid conversion involves calculating an oral morphine equivalent dose (MED) as a common currency and determining the desired doses of the alternative opioid from here [<xref rid="cit0039" ref-type="bibr">39</xref>]. The dose of the new opioid should be sufficient to achieve meaningful analgesia without toxicity or withdrawal symptoms. Unfortunately, the substantial interindividual variability that exists in opioid pharmacokinetic and pharmacodynamic profiles means that often these equianalgesic tables can often be somewhat of a misnomer [<xref rid="cit0040" ref-type="bibr">40</xref>]. Furthermore, reported doses are typically based on acute and not chronic dosing based on single-dose studies of healthy opioid-na&#239;ve participants [<xref rid="cit0016" ref-type="bibr">16</xref>]. This ignores the concept of incomplete opioid cross-tolerance whereby tolerance develops to one opioid but incompletely to others, which can lead to an overestimation of the equianalgesic dose of the alternative opioid [<xref rid="cit0039" ref-type="bibr">39</xref>]. Typically, an &#8216;automatic dose reduction window of 25&#8211;50% of calculated dose of opioid is recommended to avoid an inadvertently excessive dose of the new opioid [<xref rid="cit0039" ref-type="bibr">39</xref>].</p><p>Rotating to or from methadone is particularly fraught with difficulties and many opioid conversion tables and guidelines are conspicuous by the absence of methadone or include a disclaimer stating &#8220;seek expert opinion&#8221; [<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref>]. Due to its unique pharmacodynamic and pharmacokinetic profile outlined above with large interindividual differences in drug clearance, equianalgesic doses cannot be accurately predicted [<xref rid="cit0016" ref-type="bibr">16</xref>]. Conversion ratios from morphine to methadone vary depending on the opioid dose and have been reported to follow non-linear ratios. For example, when starting a patient on methadone, a conversion ratio of 4:1&#160;has been used for MED under 90&#8201;mg, a 5:1 ratio for MED between 90-400&#8201;mg and a 10:1 ratio over 400&#8201;mg MED (<xref rid="t0001" ref-type="table">Table 1</xref>) [<xref rid="cit0016" ref-type="bibr">16</xref>]. However, wide variations in morphine to methadone conversion have been reported anywhere from 4:1 to greater than 37.5:1 [<xref rid="cit0016" ref-type="bibr">16</xref>]. Ratios between 4&#8211;10:1&#160;have been most commonly used [<xref rid="cit0016" ref-type="bibr">16</xref>]. The recommended automatic dose reduction has been reported as high as 75&#8211;90% when switching to methadone [<xref rid="cit0043" ref-type="bibr">43</xref>]. Other patient factors which may affect methadone conversion include current pain severity, rapidity of opioid escalation, functional status, concomitant medication therapy, possible drug interactions, genetic profile and other medical co-morbidities such as hepatic or renal insufficiency [<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>] (Box 1). For example, if opioid rotation occurs in the setting of uncontrolled pain or escalating opioid-induced hyperalgesia, equianalgesic dosing will be far more unpredictable in comparison to opioid rotation for preference or convenience [<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>].
<boxed-text id="ubt0001" position="float" orientation="portrait"><label>Box 1.</label><caption><p>Factors affecting methadone conversion to other opioids during acute pain presentation.</p></caption><p><italic toggle="yes">Opioid-related factors</italic></p><p>&#8195;Current opioid dose</p><p>&#8195;Duration of opioid therapy</p><p>&#8195;Rapidity of opioid escalation</p><p>&#8195;Presence of opioid tolerance</p><p>&#8195;Presence of opioid-induced hyperalgesia</p><p>&#8195;Target opioid and route of administration</p><p><italic toggle="yes">Patient factors</italic></p><p>&#8195;Reason for rotation (patient preference or uncontrolled pain)</p><p>&#8195;Current pain severity</p><p>&#8195;Age</p><p>&#8195;Genetic profile (e.g., CYP 3A4 profile)</p><p>&#8195;Medical co-morbidity (e.g., hepatic or renal insufficiency)</p><p>&#8195;Concomitant medications and possible drug interactions</p><p>&#8195;Functional status</p><p><italic toggle="yes">Situational factors</italic></p><p>&#8195;Level of monitoring (critical care or ward)</p><p>&#8195;Level of expertise in managing opioid conversion</p><p>&#8195;Timeframe for conversion</p><p>&#8195;Follow-up plan for recommencing methadone</p></boxed-text><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Suggested dose conversion ratios from morphine to methadone [<xref rid="cit0037" ref-type="bibr">37</xref>].</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Morphine dose (mg/day)</th><th align="center" colspan="1" rowspan="1">Morphine:methadone equianalgesic dose ratio</th><th align="center" colspan="1" rowspan="1">Methadone starting dose</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">30&#8211;90</td><td align="center" colspan="1" rowspan="1">4:1</td><td align="left" colspan="1" rowspan="1">e.g. 60&#8201;mg morphine&#8201;=&#8201;15&#8201;mg methadone</td></tr><tr><td align="left" colspan="1" rowspan="1">90&#8211;400</td><td align="center" colspan="1" rowspan="1">5:1</td><td align="left" colspan="1" rowspan="1">e.g. 100&#8201;mg morphine&#8201;=&#8201;20&#8201;mg methadone</td></tr><tr><td align="left" colspan="1" rowspan="1">&gt;400</td><td align="center" colspan="1" rowspan="1">10:1</td><td align="left" colspan="1" rowspan="1">e.g. 450&#8201;mg morphine&#8201;=&#8201;45&#8201;mg methadone (30&#8201;mg maximum suggested methadone starting dose outside of hospital)</td></tr></tbody></table></table-wrap></p><p>The significant majority of literature on methadone conversion refers to conversion from another opioid to methadone and not the other way around. The conversion ratio is not necessarily bidirectional [<xref rid="cit0016" ref-type="bibr">16</xref>]. In a study that assessed conversion from methadone to MED, median ratios reported were 8.25:1 (interquartile range 4.37&#8211;11.3:1) [<xref rid="cit0046" ref-type="bibr">46</xref>]. Other studies have used ratios between 4&#8211;9:1 [<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0047" ref-type="bibr">47</xref>]. To complicate matters further, as methadone possesses NMDA-receptor antagonism which has been implicated in preventing central sensitization and reversing opioid tolerance, stopping methadone after chronic exposure can further worsen the situation by creating a rebound increase in tolerance to other opioids and facilitation of nociception transmission [<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0048" ref-type="bibr">48</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>]. All of these factors taken together constitute a substantial barrier to accurately calculating an equianalgesic morphine dose from methadone.</p><p>In reality, conversion to morphine from methadone should not be thought of as a mathematical process of dose calculation, but rather a package of care whereby patients are appropriately selected, a sensible starting conversion dose is chosen (likely between 4&#8211;10:1) and conversion initiated over a timeframe consistent with the therapeutic goals [<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>] (<xref rid="f0001" ref-type="fig">Figure 1</xref>). The response to therapy should be monitored closely with a low threshold for dose titration or additional short-acting opioids provided during the up-titration phase. This process should be individualized based on patient factors outlined in Box 1 and overseen by an experienced team. In case one above, a patient who was previously on 125&#8201;mg methadone daily is converted to 500&#8201;mg MED per day (4:1 dose conversion). This can be reduced by 50% taking into account incomplete opioid cross-tolerance (500&#8201;mg x 0.5&#8201;=&#8201;250&#8201;mg MED) and converted to a parenteral dose based on the oral bioavailability of the opioid (oral morphine approximately 33% &#8722; 250&#8201;mg x 0.33&#8201;=&#8201;82.5&#8201;mg). An hourly IV morphine infusion of 3&#8211;3.5&#8201;mg/hr could be commenced to cover baseline opioid requirements (72-84&#8201;mg IV morphine in 24&#8201;hours) [<xref rid="cit0043" ref-type="bibr">43</xref>]. Separately, PCA morphine could be commenced at 2&#8201;mg IV bolus with a lockout period of 5&#8201;minutes to treat the acute postoperative pain. Opioid dose titration can be instituted if required based on the clinical effect. For example, if the hourly IV morphine infusion is providing 72-84&#8201;mg in 24&#8201;hours and the additional bolus PCA morphine dose amounts to a further 100&#8201;mg morphine per day, these can be added to get the total IV morphine daily dose (total IV morphine 172-184&#8201;mg in 24&#8201;hours, or approximately 516-552&#8201;mg MED). This patient should be closely monitored for pain, respiratory and CNS depression, and the ward staff should be informed of the patient&#8217;s unique requirements [<xref rid="cit0050" ref-type="bibr">50</xref>]. If analgesia is suboptimal, nonopioid analgesic options should be optimized including regional analgesic techniques and nonpharmacological options, including patient reassurance and advice regarding optimal use of the PCA. NMDA-receptor antagonists such as ketamine often have a role here [<xref rid="cit0051" ref-type="bibr">51</xref>]. Failing these, an increase in the total opioid dose may be required, either by increasing the background infusion or the PCA bolus dose. This should be determined by calculation of the total expected MED, the patient&#8217;s reported pain and their pattern of PCA usage.</p></sec><sec disp-level="2" id="s0002-s2008"><label>2.8.</label><title>Stigma and misinformation</title><p>The tangled interplay of acute pain, OUD and addiction produces an additional layer of complexity for clinicians. Misconceptions can abound in this patient cohort leading to substance use stigma, which can hinder access to appropriate patient centered, evidence-based healthcare in this population [<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>]. Stigma can be multi-faceted through structural, social or internalized causes. Social stigma among misinformed healthcare professionals may lead to negative emotional reactions, stereotyping and discrimination [<xref rid="cit0052" ref-type="bibr">52</xref>]. As a result of these misconceptions, many of these patients&#8217; reports of genuine severe pain get labeled as &#8220;drug-seeking behaviour&#8221; even though this population is more susceptible to untreated severe pain [<xref rid="cit0018" ref-type="bibr">18</xref>]. This is illustrated in case one, where the patient&#8217;s history of opioid dependence and psychiatric illness can create an anchoring bias among clinicians, whereby pleas for analgesia are &#8220;anchored&#8221; within the context of her drug and psychiatric history and instead may be dismissed as &#8220;demanding&#8221; or &#8220;drug-seeking,&#8221; especially as she already has a PCA [<xref rid="cit0053" ref-type="bibr">53</xref>]. This can be a deeply undignifying experience for any patient and we should strive to avoid this. Patients&#8217; reports of pain should be respected, as outlined in the most recent IASP definition of pain [<xref rid="cit0054" ref-type="bibr">54</xref>]. Internalized &#8216;self-stigma&#8217; may reduce the likelihood of these patients requesting analgesia or accessing appropriate healthcare through self-devaluation or shame. Certain medical issues, like OUD, can be challenging for patients to self-disclose and many may not have revealed their illness to close family members or other healthcare providers. The context and environment that we deliver medical care is important component of preserving the dignity of our patients. Case one above illustrates how a patient&#8217;s history of OUD can be broadcast to other patients within earshot in an open surgical bay due to inadequately treated pain and pleas for additional analgesia from the patient. A request for pain relief does not equate to an automatic right to opioid medications, however, it should guarantee access to an unbiased medical evaluation [<xref rid="cit0055" ref-type="bibr">55</xref>]. Appropriate requests for analgesia and addiction can be difficult to untangle on occasion, particularly when a drug with a known addictive potential is involved and the patient has a history of addiction or a substance use disorder; however, we should aim to ensure that pain in vulnerable patients is not left under-treated and that those with OUD are treated with dignity and respect [<xref rid="cit0004" ref-type="bibr">4</xref>].</p></sec></sec><sec disp-level="1" id="s0003"><label>3.</label><title>Future perspective</title><p>Further research using real-world data is needed to provide clearer guidance for clinicians on safe methadone conversion given the lack of scientific literature on the topic and the multitude of challenges posed by this cohort of patients.</p></sec><sec disp-level="1" id="s0004"><label>4.</label><title>Conclusion</title><p>As clinicians, we need to understand the pharmacological and psychosocial complexity behind acute pain in those with a history of opioid use disorder. Methadone possesses unique pharmacological considerations that require careful monitoring and individualized treatment. Treatment of acute pain in this group involves uninterrupted opioid agonist therapy to meet the baseline opioid requirements and pro-active and aggressive pain management, incorporating non-opioid and non-pharmacological techniques, along with patient reassurance to reduce anxiety. Dose titration based on patient response is frequently required. We should strive to deliver care to this group of patients as compassionately as possible, preserving patient dignity, respect and privacy, while being mindful of the real risks of addiction and opioid diversion.</p></sec></body><back><sec disp-level="1" id="s0005"><title>Article highlights</title><p>
<bold>Introduction</bold>
</p><p>
<list list-type="bullet" id="list_0001"><list-item><p>Chronic methadone treatment is increasingly utilized for opioid use disorder (OUD) and chronic pain management.</p></list-item><list-item><p>Methadone presents unique challenges due to its complex pharmacokinetics and pharmacodynamics.</p></list-item><list-item><p>Individual variations in how methadone is metabolized can complicate treatment.</p></list-item><list-item><p>Issues such as tolerance, opioid-induced hyperalgesia, and the risk of respiratory depression in overdose are important considerations.</p></list-item><list-item><p>Stigma surrounding opioid use can affect access to care for patients receiving methadone treatment.</p></list-item><list-item><p>Three case studies are presented to explore management considerations for chronic methadone patients in hospitals.</p></list-item></list></p><p>
<bold>Case 1: Continuing Baseline Methadone in the Perioperative Setting</bold>
</p><p>
<list list-type="bullet" id="list_0002"><list-item><p>A patient on stable methadone therapy is hospitalized for emergency surgery requiring an emergency laparotomy and a period of nil per oral (NPO) and resultant discontinuation of regular methadone.</p></list-item><list-item><p>Numerous challenges exist around discontinuing baseline methadone in order to cover baseline opioid requirements and treat acute pain in the setting of major surgery effectively.</p></list-item></list></p><p>
<bold>Case 2: Verifying Methadone Doses Prescribed in the Community</bold>
</p><p>
<list list-type="bullet" id="list_0003"><list-item><p>A patient admitted for surgery had not been consuming his full prescribed methadone dose in the community in order to sell a portion of it. He was administered the full dose under nursing supervision while in hospital in accordance with hospital policy.</p></list-item><list-item><p>The case illustrates the importance of verifying patient-supplied medication histories in hospitals.</p></list-item></list></p><p>
<bold>Case 3: Consumption of Nonprescribed Methadone in the Community</bold>
</p><p>
<list list-type="bullet" id="list_0004"><list-item><p>A female patient was consuming non-prescribed methadone to manage chronic abdominal pain, complicating her hospital treatment.</p></list-item><list-item><p>The importance of a thorough assessment of patient medication histories prior to surgery is highlighted.</p></list-item><list-item><p>The case indicates that non prescribed use of methadone can lead to insufficiently managed postoperative pain, requiring careful planning for analgesia.</p></list-item><list-item><p>Collaboration with addiction and chronic pain management teams helps ensure comprehensive care and appropriate follow-up after discharge.</p></list-item></list></p><p>
<bold>Discussion</bold>
</p><p>
<list list-type="bullet" id="list_0005"><list-item><p><bold>Treatment of Opioid Use Disorder (OUD)</bold>:</p><p>
<list list-type="bullet" id="list_0006"><list-item><p>Methadone and buprenorphine are first line treatments in the management of OUD with a demonstrated reduction in opioid-related and all-cause mortality.</p></list-item><list-item><p>Methadone and buprenorphine occupy the opioid receptor thereby offsetting opioid withdrawal symptoms and attenuating opioid activity at this site, while naltrexone blocks the effect of other opioid agonist</p></list-item></list>
</p></list-item><list-item><p><bold>Unique Pharmacokinetics and Pharmacodynamics</bold>:</p><p>
<list list-type="bullet"><list-item><p>Methadone&#8217;s long-acting properties and complex pharmacokinetics and pharmacodynamics, as well as nonlinear conversion ratios to other opioids necessitate special consideration in pain management.</p></list-item></list>
</p></list-item><list-item><p><bold>Acute Pain in OUD</bold>:</p><p>
<list list-type="bullet" id="list_0008"><list-item><p>Managing acute pain in methadone-treated patients poses unique challenges due to opioid tolerance and heightened pain sensitivity.</p></list-item><list-item><p>Misperceptions may exist that the usual maintenance methadone dose may be sufficient for acute pain.</p></list-item><list-item><p>The usual principles of treating acute pain apply in those on chronic methadone treatment including optimizing non-opioids first and employing multi-modal methods of analgesia including regional analgesic techniques.</p></list-item><list-item><p>Patients on chronic methadone treatment, however, will typically require an increase in their total opioid dose.</p></list-item></list>
</p></list-item><list-item><p><bold>Prescribing Reluctances</bold>:</p><p>
<list list-type="bullet" id="list_0009"><list-item><p>Concerns about overdose and relapse can lead to hesitancy in prescribing additional opioids to those with OUD.</p></list-item><list-item><p>Under-treatment of pain can exacerbate stress responses and potential for relapse.</p></list-item><list-item><p>Accurate assessments and proactive pain management strategies are critical for optimal patient outcomes.</p></list-item></list>
</p></list-item><list-item><p><bold>Peri-operative Analgesia Challenges</bold>:</p><p>
<list list-type="bullet" id="list_0010"><list-item><p>For those on chronic methadone treatment requiring surgery, baseline oral methadone should always be continued where possible.</p></list-item><list-item><p>Alternative administration methods (intramuscular or subcutaneous) may be necessary if oral routes are unavailable.</p></list-item><list-item><p>Correct dosing and conversion strategies are vital due to the unique characteristics of methadone.</p></list-item></list></p></list-item><list-item><p><bold>Stigma and Misinformation</bold>:</p><p>
<list list-type="bullet" id="list_0011"><list-item><p>Societal and healthcare provider stigma can hinder access to appropriate care for patients with OUD.</p></list-item><list-item><p>This can lead to inadequate pain management and negative patient experiences.</p></list-item><list-item><p>Education and awareness among healthcare personnel are paramount for improving treatment outcomes and patient dignity.</p></list-item></list></p></list-item></list>
</p><p>
<bold>Conclusion</bold>
</p><p>
<list list-type="bullet" id="list_0012"><list-item><p>An understanding of the pharmacological and psychosocial complexities of methadone is crucial for effective pain management in patients with OUD.</p></list-item><list-item><p>Customized treatment plans must focus on maintaining opioid therapy, alongside comprehensive pain management techniques.</p></list-item></list></p><p>Stigma which can lead to stereotyping, discrimination and untreated acute pain, should be avoided.</p></sec><sec disp-level="1" id="s0006"><title>Author contribution statement</title><p>CFM, SW and JF designed and constructed the manuscript, including patient consent and recruitment, data collection, and data analysis. CFM prepared the manuscript draft with important intellectual input from SW and JF. All authors reviewed the manuscript and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement" disp-level="1" id="s0007"><title>Disclosure statement</title><p>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</p></sec><sec disp-level="1" id="s0008"><title>Ethics approval statement</title><p>Ethics committee approval was not required for a case series and review. St. James&#8217; Hospital (SJH)/Tallaght University Hospital (TUH) Joint Research Ethics Committee (REC) do not require formal approval for case series involving less that 5 participants. Informed patient consent was obtained prior to the inclusion of all cases presented in this series in anonymized form.</p></sec><sec sec-type="data-availability" disp-level="1" id="s0009"><title>Data availability statement</title><p>The data that support the findings of this study are available on request from the corresponding author, CFM.</p></sec><ref-list><title>References</title><p>
<bold>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</bold>
</p><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Kharrazi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bodycombe</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study</article-title>. <source>BMC Med</source>. <year>2018</year>;<volume>16</volume>(<issue>1</issue>):<fpage>69</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-018-1058-y</pub-id><pub-id pub-id-type="pmid">29764482</pub-id><pub-id pub-id-type="pmcid">PMC5954462</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coluzzi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bifulco</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cuomo</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>The challenge of perioperative pain management in opioid-tolerant patients</article-title>. <source>Ther Clin Risk Manag</source>. <year>2017</year>;<volume>13</volume>:<fpage>1163</fpage>&#8211;<lpage>1173</lpage>. doi: <pub-id pub-id-type="doi">10.2147/TCRM.S141332</pub-id><pub-id pub-id-type="pmid">28919771</pub-id><pub-id pub-id-type="pmcid">PMC5592950</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benyamin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Trescot</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Datta</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Opioid complications and side effects</article-title>. <source>Pain Physician</source>. <year>2008</year>;<volume>11</volume>(<issue>2 Suppl</issue>):<fpage>S105</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.36076/ppj.2008/11/S105</pub-id><pub-id pub-id-type="pmid">18443635</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brennan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lohman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gwyther</surname><given-names>L.</given-names></string-name></person-group><article-title>Access to pain management as a human right</article-title>. <source>Am J Public Health</source>. <year>2019</year>;<volume>109</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.2105/AJPH.2018.304743</pub-id><pub-id pub-id-type="pmid">32941757</pub-id><pub-id pub-id-type="pmcid">PMC6301399</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Strang</surname><given-names>J.</given-names></string-name></person-group><article-title>Medication treatment of opioid use disorder</article-title>. <source>Biol Psychiatry</source>. <year>2020</year>;<volume>87</volume>(<issue>1</issue>):<fpage>82</fpage>&#8211;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopsych.2019.06.020</pub-id><pub-id pub-id-type="pmid">31420089</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inturrisi</surname><given-names>CE</given-names></string-name></person-group>. <article-title>Pharmacology of methadone and its isomers</article-title>. <source>Minerva Anestesiol</source>. <year>2005</year>;<volume>71</volume>(<issue>7&#8211;8</issue>):<fpage>435</fpage>&#8211;<lpage>437</lpage>.<pub-id pub-id-type="pmid">16012416</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Eissenberg</surname><given-names>T</given-names></string-name></person-group>. <article-title>The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic</article-title>. <source>Drug Alcohol Depend</source>. <year>2003</year>;<volume>70</volume>(<issue>2</issue>):<fpage>S13</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0376-8716(03)00056-5</pub-id><pub-id pub-id-type="pmid">12738347</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bernson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>Medication for opioid use disorder after nonfatal opioid overdose and association with mortality</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>(<issue>3</issue>):<fpage>137</fpage>&#8211;<lpage>145</lpage>. doi: <pub-id pub-id-type="doi">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This retrospective study of medications for opioid use disorder demonstrates the importance of effective treatment of opioid use disorder with decreased opioid-related and all-cause mortality identified for methadone and buprenorphine treatment.</bold>
</p></note></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Trinh</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment</article-title>. <source>Addiction</source>. <year>2009</year>;<volume>104</volume>(<issue>7</issue>):<fpage>1193</fpage>&#8211;<lpage>1200</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1360-0443.2009.02627.x</pub-id><pub-id pub-id-type="pmid">19563562</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bell</surname><given-names>J</given-names></string-name></person-group>. <article-title>Pharmacological maintenance treatments of opiate addiction</article-title>. <source>Br J Clin Pharmacol</source>. <year>2014</year>;<volume>77</volume>(<issue>2</issue>):<fpage>253</fpage>&#8211;<lpage>263</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12051</pub-id><pub-id pub-id-type="pmid">23210630</pub-id><pub-id pub-id-type="pmcid">PMC4014029</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Faggiano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vigna-Taglianti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Versino</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Methadone maintenance at different dosages for opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2003</year>;<volume>2003</volume>(<issue>3</issue>):<fpage>Cd002208</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD002208</pub-id><pub-id pub-id-type="pmid">12917925</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hb</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Akil</surname><given-names>H</given-names></string-name></person-group>. <article-title>Opioid analgesics</article-title>. Goodman &amp; Gilman&#8217;s the pharmacological basis of therapeutics. <year>2001</year>;<volume>11</volume>:<fpage>547</fpage>&#8211;<lpage>590</lpage>.</mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gorman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Elliott</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Inturrisi</surname><given-names>CE</given-names></string-name></person-group>. <article-title>The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord</article-title>. <source>Neurosci Lett</source>. <year>1997</year>;<volume>223</volume>(<issue>1</issue>):<fpage>5</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0304-3940(97)13391-2</pub-id><pub-id pub-id-type="pmid">9058409</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hagen</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Moulin</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Brasher</surname><given-names>PM</given-names></string-name>, et al</person-group>. <article-title>A formal feasibility study of sublingual methadone for breakthrough cancer pain</article-title>. <source>Palliat Med</source>. <year>2010</year>;<volume>24</volume>(<issue>7</issue>):<fpage>696</fpage>&#8211;<lpage>706</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0269216310375999</pub-id><pub-id pub-id-type="pmid">20671005</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sunilkumar</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Lockman</surname><given-names>K</given-names></string-name></person-group>. <article-title>Practical pharmacology of methadone: a long-acting opioid</article-title>. <source>Indian J Palliat Care</source>. <year>2018</year>;<volume>24</volume>(<issue>Suppl 1</issue>):<fpage>S10</fpage>&#8211;<lpage>s4</lpage>. doi: <pub-id pub-id-type="doi">10.4103/IJPC.IJPC_180_17</pub-id><pub-id pub-id-type="pmid">29497249</pub-id><pub-id pub-id-type="pmcid">PMC5806300</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weschules</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Bain</surname><given-names>KT</given-names></string-name></person-group>. <article-title>A systematic review of opioid conversion ratios used with methadone for the treatment of pain</article-title>. <source>Pain Med</source>. <year>2008</year>;<volume>9</volume>(<issue>5</issue>):<fpage>595</fpage>&#8211;<lpage>612</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1526-4637.2008.00461.x</pub-id><pub-id pub-id-type="pmid">18565004</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>NICE</collab></person-group>. <source>Opioid dependence clinical knowledge summaries</source>. <year>2025</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cks.nice.org.uk/topics/opioid-dependence/" ext-link-type="uri">https://cks.nice.org.uk/topics/opioid-dependence/</ext-link></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alford</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Samet</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Acute pain management for patients receiving maintenance methadone or buprenorphine therapy</article-title>. <source>Ann Intern Med</source>. <year>2006</year>;<volume>144</volume>(<issue>2</issue>):<fpage>127</fpage>&#8211;<lpage>134</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-144-2-200601170-00010</pub-id><pub-id pub-id-type="pmid">16418412</pub-id><pub-id pub-id-type="pmcid">PMC1892816</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vadivelu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mitra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaye</surname><given-names>AD</given-names></string-name>, et al</person-group>. <article-title>Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient</article-title>. <source>Best Pract Res Clin Anaesthesiol</source>. <year>2014</year>;<volume>28</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>101</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bpa.2014.02.003</pub-id><pub-id pub-id-type="pmid">24815969</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dowell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ragan</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, et al</person-group>. <article-title>CDC clinical practice guideline for prescribing opioids for pain &#8212; United States, 2022</article-title>. <source>MMWR Recomm Rep</source>. <year>2022</year>;<volume>71</volume>(<issue>3</issue>):<fpage>1</fpage>&#8211;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.15585/mmwr.rr7103a1</pub-id><pub-id pub-id-type="pmcid">PMC9639433</pub-id><pub-id pub-id-type="pmid">36327391</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>J</given-names></string-name></person-group>. <article-title>Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy</article-title>. <source>Pain</source>. <year>2002</year>;<volume>100</volume>(<issue>3</issue>):<fpage>213</fpage>&#8211;<lpage>217</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0304-3959(02)00422-0</pub-id><pub-id pub-id-type="pmid">12467992</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Compton</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Charuvastra</surname><given-names>VC</given-names></string-name>, <string-name name-style="western"><surname>Kintaudi</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Pain responses in methadone-maintained opioid abusers</article-title>. <source>J Pain Symptom Manage</source>. <year>2000</year>;<volume>20</volume>(<issue>4</issue>):<fpage>237</fpage>&#8211;<lpage>245</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0885-3924(00)00191-3</pub-id><pub-id pub-id-type="pmid">11027904</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eyler</surname><given-names>EC</given-names></string-name></person-group>. <article-title>Chronic and acute pain and pain management for patients in methadone maintenance treatment</article-title>. <source>Am J Addict</source>. <year>2013</year>;<volume>22</volume>(<issue>1</issue>):<fpage>75</fpage>&#8211;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1521-0391.2013.00308.x</pub-id><pub-id pub-id-type="pmid">23398230</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karasz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zallman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>The experience of chronic severe pain in patients undergoing methadone maintenance treatment</article-title>. <source>J Pain Symptom Manage</source>. <year>2004</year>;<volume>28</volume>(<issue>5</issue>):<fpage>517</fpage>&#8211;<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2004.02.025</pub-id><pub-id pub-id-type="pmid">15504628</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kantor</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Cantor</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tom</surname><given-names>E</given-names></string-name></person-group>. <article-title>A study of hospitalized surgical patients on methadone maintenance</article-title>. <source>Drug Alcohol Depend</source>. <year>1980</year>;<volume>6</volume>(<issue>3</issue>):<fpage>163</fpage>&#8211;<lpage>173</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0376-8716(80)90455-X</pub-id><pub-id pub-id-type="pmid">6107237</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanks</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Twycross</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Lloyd</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain</article-title>. <source>Anaesthesia</source>. <year>1981</year>;<volume>36</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2044.1981.tb08596.x</pub-id><pub-id pub-id-type="pmid">6894066</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eriator</surname><given-names>I</given-names></string-name></person-group>. <article-title>Narcotic analgesics for chronic pain management</article-title>. <source>Curr Rev Pain</source>. <year>1998</year>;<volume>2</volume>(<issue>4</issue>):<fpage>193</fpage>&#8211;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11916-998-0019-0</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Snow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>S</given-names></string-name></person-group>. <article-title>Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study</article-title>. <source>Subst Abus</source>. <year>2020</year>;<volume>41</volume>(<issue>4</issue>):<fpage>519</fpage>&#8211;<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1080/08897077.2019.1671942</pub-id><pub-id pub-id-type="pmid">31638862</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schug</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Goddard</surname><given-names>C</given-names></string-name></person-group>. <article-title>Recent advances in the pharmacological management of acute and chronic pain</article-title>. <source>Ann Palliat Med</source>. <year>2014</year>;<volume>3</volume>(<issue>4</issue>):<fpage>263</fpage>&#8211;<lpage>275</lpage>. doi: <pub-id pub-id-type="doi">10.3978/j.issn.2224-5820.2014.10.02</pub-id><pub-id pub-id-type="pmid">25841906</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Schug</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Mott</surname><given-names>JF</given-names></string-name>, et al</person-group>. <source>Acute pain management: scientific evidence</source>. 5th ed. <publisher-loc>Melbourne</publisher-loc>: <publisher-name>ANZCA &amp; FPM</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fultz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Senay</surname><given-names>EC</given-names></string-name></person-group>. <article-title>Guidelines for the management of hospitalized narcotics addicts</article-title>. <source>Ann Intern Med</source>. <year>1975</year>;<volume>82</volume>(<issue>6</issue>):<fpage>815</fpage>&#8211;<lpage>818</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-82-6-815</pub-id><pub-id pub-id-type="pmid">1138596</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>de Leon-Casasola</surname><given-names>OA</given-names></string-name>, et al</person-group>. <article-title>Management of postoperative pain: a clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists&#8217; committee on regional anesthesia, executive committee, and administrative council</article-title>. <source>J Pain</source>. <year>2016</year>;<volume>17</volume>(<issue>2</issue>):<fpage>131</fpage>&#8211;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpain.2015.12.008</pub-id><pub-id pub-id-type="pmid">26827847</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crews</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Sweeney</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Denson</surname><given-names>DD</given-names></string-name></person-group>. <article-title>Clinical efficacy of methadone in patients refractory to other &#956;&#8208;opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross&#8208;tolerance among opioid agonist analgesics</article-title>. <source>Cancer</source>. <year>1993</year>;<volume>72</volume>(<issue>7</issue>):<fpage>2266</fpage>&#8211;<lpage>2272</lpage>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19931001)72:7&amp;#x0003c;2266::AID-CNCR2820720734&amp;#x0003e;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">7690683</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manfredi</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Gonzales</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Cheville</surname><given-names>AL</given-names></string-name>, et al</person-group>. <article-title>Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy</article-title>. <source>J Pain Symptom Manage</source>. <year>2001</year>;<volume>21</volume>(<issue>2</issue>):<fpage>169</fpage>&#8211;<lpage>174</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0885-3924(00)00252-9</pub-id><pub-id pub-id-type="pmid">11226767</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="book">Wolters Kluwer. <source>Drug facts and comparisons</source>. Philadelphia (PA): Wolters Kluwer Health; <year>2007</year>. p. <fpage>1082</fpage>.</mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaiova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blinderman</surname><given-names>CD</given-names></string-name>, et al</person-group>. <article-title>Consensus guideline on parenteral methadone use in pain and palliative care</article-title>. <source>Palliat Support Care</source>. <year>2008</year>;<volume>6</volume>(<issue>2</issue>):<fpage>165</fpage>&#8211;<lpage>176</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1478951508000254</pub-id><pub-id pub-id-type="pmid">18501052</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neto</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>de Almeida Correa</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Methadone patient-controlled analgesia for postoperative pain: a randomized, controlled, double-blind study</article-title>. <source>J Anesth</source>. <year>2014</year>;<volume>28</volume>(<issue>4</issue>):<fpage>505</fpage>&#8211;<lpage>510</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00540-013-1785-3</pub-id><pub-id pub-id-type="pmid">24445560</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mercadante</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Caraceni</surname><given-names>A</given-names></string-name></person-group>. <article-title>Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review</article-title>. <source>Palliat Med</source>. <year>2011</year>;<volume>25</volume>(<issue>5</issue>):<fpage>504</fpage>&#8211;<lpage>515</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0269216311406577</pub-id><pub-id pub-id-type="pmid">21708857</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This systematic review outlines the existing literature for conversion between opioids and highlights the highly variable conversion ratio when switching from different opioids to methadone.</bold>
</p></note></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moryl</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Santiago-Palma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kornick</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain</article-title>. <source>Pain</source>. <year>2002</year>;<volume>96</volume>(<issue>3</issue>):<fpage>325</fpage>&#8211;<lpage>328</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0304-3959(01)00465-1</pub-id><pub-id pub-id-type="pmid">11973005</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knotkova</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fine</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name></person-group>. <article-title>Opioid rotation: the science and the limitations of the equianalgesic dose table</article-title>. <source>J Pain Symptom Manage</source>. <year>2009</year>;<volume>38</volume>(<issue>3</issue>):<fpage>426</fpage>&#8211;<lpage>439</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2009.06.001</pub-id><pub-id pub-id-type="pmid">19735903</pub-id></mixed-citation><note><p>
<bold>&#8226; This review article highlights some of the potential pitfalls of equianalgesic dosing tables and outlines the need for updated data.</bold>
</p></note></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Medicine FoP</collab></person-group>. <article-title>Dose equivalents and changing opioids</article-title>. <year>2020</year>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids" ext-link-type="uri">https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids</ext-link></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ANZCA F</collab></person-group>. <article-title>Opioid dose equivalence calculation table</article-title>. <year>2021</year>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.anzca.edu.au/getattachment/6892fb13-47fc-446b-a7a2-11cdfe1c9902/PS01(PM)-(Appendix)-Opioid-Dose-Equivalence-Calculation-Table" ext-link-type="uri">https://www.anzca.edu.au/getattachment/6892fb13-47fc-446b-a7a2-11cdfe1c9902/PS01(PM)-(Appendix)-Opioid-Dose-Equivalence-Calculation-Table</ext-link></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fine</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name></person-group>. <article-title>Establishing &#8220;best practices&#8221; for opioid rotation: conclusions of an expert panel</article-title>. <source>J Pain Symptom Manage</source>. <year>2009</year>;<volume>38</volume>(<issue>3</issue>):<fpage>418</fpage>&#8211;<lpage>425</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2009.06.002</pub-id><pub-id pub-id-type="pmid">19735902</pub-id><pub-id pub-id-type="pmcid">PMC4065110</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mercadante</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name></person-group>. <article-title>Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia</article-title>. <source>J Pain Symptom Manage</source>. <year>2001</year>;<volume>21</volume>(<issue>3</issue>):<fpage>255</fpage>&#8211;<lpage>264</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0885-3924(00)00236-0</pub-id><pub-id pub-id-type="pmid">11239748</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mercadante</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arcuri</surname><given-names>E</given-names></string-name></person-group>. <article-title>Hyperalgesia and opioid switching</article-title>. <source>Am J Hosp Palliat Care</source>. <year>2005</year>;<volume>22</volume>(<issue>4</issue>):<fpage>291</fpage>&#8211;<lpage>294</lpage>. doi: <pub-id pub-id-type="doi">10.1177/104990910502200411</pub-id><pub-id pub-id-type="pmid">16082916</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lawlor</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study</article-title>. <source>Cancer</source>. <year>1998</year>;<volume>82</volume>(<issue>6</issue>):<fpage>1167</fpage>&#8211;<lpage>1173</lpage>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0142(19980315)82:6&amp;#x0003c;1167::AID-CNCR23&amp;#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">9506365</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mercadante</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferrera</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Villari</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Rapid switching between transdermal fentanyl and methadone in cancer patients</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>(<issue>22</issue>):<fpage>5229</fpage>&#8211;<lpage>5234</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2005.13.128</pub-id><pub-id pub-id-type="pmid">16051965</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dickenson</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>AF</given-names></string-name></person-group>. <article-title>Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation</article-title>. <source>Neuropharmacology</source>. <year>1987</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1235</fpage>&#8211;<lpage>1238</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0028-3908(87)90275-9</pub-id><pub-id pub-id-type="pmid">2821443</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elliott</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kest</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Man</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development</article-title>. <source>Neuropsychopharmacology</source>. <year>1995</year>;<volume>13</volume>(<issue>4</issue>):<fpage>347</fpage>&#8211;<lpage>356</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0893-133X(95)00083-P</pub-id><pub-id pub-id-type="pmid">8747759</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Tumber</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Gourlay</surname><given-names>D</given-names></string-name></person-group>. <article-title>Expos&#233; de synth&#232;se : Traitement de la douleur p&#233;riop&#233;ratoire chez les patients sous th&#233;rapie &#224; la m&#233;thadone</article-title>. <source>Can J Anaesth</source>. <year>2005</year>;<volume>52</volume>(<issue>5</issue>):<fpage>513</fpage>&#8211;<lpage>523</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF03016532</pub-id><pub-id pub-id-type="pmid">15872131</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Orhurhu</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Ly</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Ketamine in acute and chronic pain management</article-title>. <source>StatPearls</source>. <year>2025</year>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK539824/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK539824/</ext-link><pub-id pub-id-type="pmid">30969646</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spata</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lear</surname><given-names>MK</given-names></string-name>, et al</person-group>. <article-title>Substance use stigma: a systematic review of measures and their psychometric properties</article-title>. <source>Drug Alcohol Depend Rep</source>. <year>2024</year>;<volume>11</volume>:<fpage>100237</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dadr.2024.100237</pub-id><pub-id pub-id-type="pmid">38779475</pub-id><pub-id pub-id-type="pmcid">PMC11108807</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coughlan</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Mullins</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Kiernan</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Diagnosing, fast and slow</article-title>. <source>Postgrad Med J</source>. <year>2021</year>;<volume>97</volume>(<issue>1144</issue>):<fpage>103</fpage>&#8211;<lpage>109</lpage>. doi: <pub-id pub-id-type="doi">10.1136/postgradmedj-2019-137412</pub-id><pub-id pub-id-type="pmid">32595113</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raja</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Carr</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>The revised international association for the study of pain definition of pain: concepts, challenges, and compromises</article-title>. <source>Pain</source>. <year>2020</year>;<volume>161</volume>(<issue>9</issue>):<fpage>1976</fpage>&#8211;<lpage>1982</lpage>. doi: <pub-id pub-id-type="doi">10.1097/j.pain.0000000000001939</pub-id><pub-id pub-id-type="pmid">32694387</pub-id><pub-id pub-id-type="pmcid">PMC7680716</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Pain Summit Of The International Association For The Study Of P</collab></person-group>. <article-title>Declaration of Montr&#233;al: declaration that access to pain management is a fundamental human right</article-title>. <source>J Pain Palliat Care Pharmacother</source>. <year>2011</year>;<volume>25</volume>(<issue>1</issue>):<fpage>29</fpage>&#8211;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.3109/15360288.2010.547560</pub-id><pub-id pub-id-type="pmid">21426215</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>